---
title: "What's Going On With Recursion Pharmaceuticals Stock On Thursday?"
description: "Recursion Pharmaceuticals' stock is trading higher after Nvidia disclosed a $75.9 million stake in the company. Recursion utilizes a hybrid lab-to-cloud platform combining biology, bioinformatics, and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/108010202.md"
published_at: "2024-02-15T15:05:35.000Z"
---

# What's Going On With Recursion Pharmaceuticals Stock On Thursday?

> Recursion Pharmaceuticals' stock is trading higher after Nvidia disclosed a $75.9 million stake in the company. Recursion utilizes a hybrid lab-to-cloud platform combining biology, bioinformatics, and AI to identify treatments for diseases. The stock has seen a 62.52% rise in the past 3 months.

**Recursion Pharmaceuticals Inc** (NASDAQ:RXRX) shares are trading higher after **Nvidia Corp** (NASDAQ:NVDA), in its 13F filing, disclosed a small stake in the company.

As per the SEC filing, Nvidia’s stake in Recursion Pharmaceuticals was valued at $75.9 million, with 7.7 million shares.

In July 2023, Nvidia disclosed a $50 million investment in Recursion.

Founded in 2013, Recursion Pharmaceuticals combines experimental biology, bioinformatics, and artificial intelligence in a hybrid lab-to-cloud platform to identify treatments for any disease that can be modeled at the cellular level.

“Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA, in July 2023.

In its press release, Recursion said it plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX Cloud for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.

The shares are trading higher on a heavy session volume of 1.595 million, compared to the average volume of 5.494 million, as per data from Benzinga Pro.

In January, Recursion Pharmaceuticals unveiled LOWE (Large Language Model-Orchestrated Workflow Engine), its new software designed to perform complex drug discovery tasks using a natural language interface, at the J.P. Morgan Healthcare Conference.

**Is RXRX A Good Stock To Buy?**

Wall Street analysts view Recursion Pharmaceuticals on the whole as a Buy, given the history of coverage over the past three months. Gil Blum from Needham in Recursion Pharmaceuticals is the most optimistic.

But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Recursion Pharmaceuticals rose 62.52%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which fell 19.96% over the past year.

A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.

**Price Action**: RXRX shares are up 6.96% at $11.68 on the last check Thursday.

### Related Stocks

- [NVD.DE - NVIDIA Corporation](https://longbridge.com/en/quote/NVD.DE.md)
- [NVDA.US - NVIDIA](https://longbridge.com/en/quote/NVDA.US.md)
- [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 黄仁勋预告 “前所未见” 的芯片新品，下一代 Feynman 架构或成焦点 | 黄仁勋预告今年的 GTC 大会上发布” 世界从未见过” 的全新芯片产品，分析认为新品可能涉及 Rubin 系列衍生产品或更具革命性的 Feynman 架构芯片，市场预期 Feynman 架构将针对推理场景进行深度优化。 | [Link](https://longbridge.com/en/news/276310964.md) |
| 学习英伟达刺激芯片销售，AMD 为 “AI 云” 借款做担保 | AMD 为扩大市场份额祭出金融 “狠招”！为初创公司 Crusoe 的 3 亿美元购芯贷款提供担保，承诺在其无客户时 “兜底” 租用芯片。这一复刻英伟达 “租卡云” 路径的策略虽能短期推高销量，但也令 AMD 在 AI 需求放缓时面临更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| 机构 “最超配” 闪迪，“最低配” 英伟达 | 据摩根士丹利最新的统计：“机构对美国大型科技股的低配程度是 17 年来最大的” 相比 2025 年 Q4 的标普 500 指数权重，“$NVDA 仍然是机构低配程度最大的大型科技股，其次是苹果、微软、亚马逊和博通，而存储巨头闪迪则是 “最超 | [Link](https://longbridge.com/en/news/276289765.md) |
| LPDDR 6 时代来临！AI 需求太猛，下一代 DRAM 将比预期更快进入市场 | LPDDR6 性能较前代提升 1.5 倍，最快下半年正式商用，英伟达、三星及高通等巨头正积极布局。目前多数 HPC 半导体设计企业考虑并行搭载 LPDDR5X 及 LPDDR6 IP，特别是在 4 纳米及以下先进制程芯片的设计中，需求出现得 | [Link](https://longbridge.com/en/news/276431575.md) |
| 传言成真？英伟达对 OpenAI 的 “1000 亿美元投资” 最终 “打了三折” | 据报道，英伟达正接近敲定对 OpenAI 最高 300 亿美元的股权投资，取代此前官宣的 1000 亿美元合作框架。原有协议因条款分歧与内部疑虑未能落地，黄仁勋亦曾强调其不具约束力。此次新融资轮规模或超 1000 亿美元，OpenAI 估值 | [Link](https://longbridge.com/en/news/276507066.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.